1979 Volume 21 Issue 11 Pages 1171-1183
Dipyridamole (Persantin) 300 mg/day, or its placebo were administered for 4 weeks to the nephrotic syndrome who had been treated by corticosteroids and their effects were compared by double blind method. 1) General improvement rate of Persantin (88.2%) was significantly (p<0.05) higher than that of placebo (46.7%) in steroid unresponsive nephrotic syndrome group. 2) As to urinary protein decreasing effect indicated by average decreasing rates of urinary protein in a week, the effect was better in Persantin group than in placebo group in the 1st and 2nd week. The same results were confirmed more evidently in the steroid unresponsive nephrotic syndrome group and also in those patient except minimal changes in histological classification. 3) As to the endogenous creatinine clearance, Persantin group showed a significantly large increase, compared with placebo group. 4) As to serum cholesterol level and triglycerid level, Persantin group showed a bigger tende-ncy to decrease, compared with placebo group. 5) As for side effects, headache, palpitation, nausea, retching, and others were observed in Persantin group. However, these were not serious and disappeared after discontinuation of administra-tion of the drug.
